Biotek-snakken — December 2019
-
"There's absolutely no comparison. You wouldn't see a response rate this high in the third- or fourth-line setting. Once you get past first- and second-line therapy, you're seeing response rates in the 20% to 30% range at best. The response rate for trastuzumab deruxtecan was so high [61%] with progression-free survival for so long [16.4 months], that it knocks all other therapies out of the park."
-
Der er bekymringer omkring bivirkningsprofilen (bl.a. ILD) og det er jo her at ZW49 virkelig gerne skulle vise sit værd, da det jo bevidst er dette Zymeworks er gået efter. Så lad os håbe på at ZW49 har effekt som DS8201 og en langt bedre bivirkningsprofil, så bliver det rigtig sjovt
-
Sukkeralf, ved du hvad det er for et antistof Zyme
har i Phase I sammen med Eli Lilly? (jf. skemaet i deres corporate presentation) -
Ang Alligator Bioscience: Det er fint med et link men hvor bliver køberne af? Johnson og Johnson har reduceret deres beholding betydeligt og der er tilsyneladende udskiftning i ledelsen . Vi er nu brudt under alltime low og der er ingen støtte at finde...
-
-
Nogen der kender forty Seven Inc. Købte lidt forleden.
-
-
God video for os amatører https://www.fortyseveninc.com/science#CD47
-
1
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind